跳至主要内容
临床试验/NCT07658170
NCT07658170招募中不适用

Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)

The Leningrad Regional Clinical Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年11月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30
试验地点
1

研究概览

简要总结

The goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors, which may help the graft survive better.

The main questions it aims to answer are:

What percentage of the fat graft's volume remains in place 3 months after radiation therapy?

What is the safety of this procedure, including its side effects and any impact on cancer returning?

Participants will:

  • Undergo standard breast-conserving surgery to remove the tumor
  • Have liposuction (fat removal) from their own belly or thighs
  • Receive a "lipobolus" (their own fat mixed with PRF) placed into the breast defect during the same surgery
  • Follow up for 12 months with ultrasound scans, physical exams, and questionnaires (BREASTQ) about their satisfaction and quality of life

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 69 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Histologically verified breast cancer (BC).
  • Disease stage from cTis to cT2 according to the TNM classification (AJCC, 8th edition).
  • Tumor grade G1 or G
  • Estrogen receptor positivity (ER+).
  • ECOG performance status =
  • Primary tumor size up to 2 cm, based solely on preoperative examination data (mammography, ultrasound, MRI).
  • Indications for breast-conserving surgery (BCS) with a breast resection extent determined by a multidisciplinary oncology board.
  • Submission of an informed voluntary consent (IVC) regarding participation in the study.
  • Ability to understand and comply with the requirements of the study protocol.

排除标准

  • Male gender.
  • Multifocal or multicentric tumor.
  • Triple-negative or HER2-positive tumor with uncontrolled disease.
  • Stage cT3 or higher or distant metastases (M1).
  • Inflammatory breast cancer.
  • Prior neoadjuvant chemotherapy or hormonal therapy.
  • Prior radiation therapy to the breast.
  • Presence of blood coagulation disorders (coagulopathy, thrombocytopathy, thrombocytopenia < 100 × 10⁹/L).
  • Taking anticoagulants or antiplatelet agents that cannot be temporarily discontinued.
  • Presence of active infectious diseases.
  • Acute autoimmune diseases.
  • Decompensated comorbidities (diabetes mellitus, cardiovascular diseases, etc.).
  • Body mass index (BMI) < 18.5 kg/m² (insufficient adipose tissue volume for liposuction).
  • Pregnancy or lactation.
  • Mental illnesses that prevent informed consent.
  • Known allergy to local anesthetics or sodium citrate.

研究者

发起方
The Leningrad Regional Clinical Hospital
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验